Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 BMN 110 placebo-controlled study in Morquio A syndrome
2010-020198-18Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Nov 2010
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elosulfase alfa in Mucopolysaccharidosis type IV A (3 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Primary efficacy endpoint. Started Nov 2010; status: completed.
02
Drugs
elosulfase alfa
03
Conditions
Mucopolysaccharidosis type IV A
Beyond the preview
Go deeper on 2010-020198-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020198-18.